News & Events

Filter Year   Keywords   > Submit

Page 2 3

ChemGenex‚??s Omapro‚?Ę Featured During ASH Oral Session

09 / 12 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro‚?Ę (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors (TKI). New data were presented at the 51st Annual American Society of Hematology Meeting in New Orleans, Louisiana.

> Read More

Pivotal Data on ChemGenex‚??s Omapro‚?Ę Highlighted at ASH Press Conference

07 / 12 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro‚?Ę (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. New data was presented at a pre-conference press showcase at the 51st Annual American Society of Hematology Annual Meeting in New Orleans, Louisiana.

> Read More

ChemGenex to Present Positive Data for Omapro‚?Ę from Multiple Clinical Trials at ASH

01 / 12 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that updated clinical data from several of its clinical trials with Omapro‚?Ę (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

> Read More

Chairman‚??s Address for ChemGenex Pharmaceuticals Limited Annual General Meeting

30 / 11 / 2009

The last twelve months have been truly transformational for ChemGenex and we sit now with the possibility of drug approvals in the world‚??s two largest pharmaceutical markets, the USA and Europe, and the potential launch of Omapro by our own commercial team in the USA next year.

> Read More

ChemGenex‚??s Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency

27 / 11 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid...

> Read More

LEO Pharma Completes Peplin Acquisition; Peplin to Continue as an Independent Subsidiary

12 / 11 / 2009

Peplin, Inc. (ASX:PLI) today announced that it has completed its merger with LEO Pharma A/S (LEO) after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. The merger consideration will be distributed to holders of common stock and CDIs promptly.

> Read More

Verva Announces Appointment of Professor Michael Cowley to its Board of Directors

11 / 11 / 2009

Verva Pharmaceuticals Ltd. today announced that Professor. Michael A. Cowley, Director of the Monash Obesity & Diabetes Institute, has joined the Company's Board as a non-executive Director. Professor Cowley is a Victorian Endowment for Science, Knowledge and Innovation (VESKI) Innovation Fellow and a Pfizer Senior Research Fellow for 2009. Recently Professor Cowley was awarded the prestigious Commonwealth Science Minister's Prize for Life Scientist of the Year.

> Read More

ChemGenex Announces FDA Accepts NDA for Omapro‚?Ę (Omacetaxine Mepesuccinate) and Grants the Filing Priority Review Status

10 / 11 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company‚??s New Drug Application (NDA) for Omapro‚?Ę (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. The NDA has also been granted Priority Review. A Priority Review designation is given to drugs that offer ...

> Read More

WOMEN‚??S SEXUAL HEALTH COMPANY CHANGES NAME IN PREPARATION FOR MARKET ENTRY TivaMed Becomes Viveve

09 / 11 / 2009

Women‚??s sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.

> Read More

Sunshine Heart - Retirement and Appointment of Director

03 / 11 / 2009

Sunshine Heart, Inc (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announces the retirement of Mr Don Rohrbaugh as a director of the Company effective 31 October 2009. The company further announces the appointment of Mr David Rosa as a director of the Company effective 1 November 2009.

> Read More

ChemGenex CEO Receives AusBiotech Award

28 / 10 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) is pleased to announce Chief Executive Officer and Managing Director Greg Collier, PhD. was recognized this morning for his outstanding contribution to the advancement of biotechnology in Australia.

> Read More

KaloBios‚?? KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients

15 / 10 / 2009

Phase 1/2 clinical trial results with KB001, a Humaneered‚?Ę, high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients showed an acceptable safety profile as well as trends toward reducing tissue inflammation and clearance of the bacterium. Results of the multi-center, randomized, double-blind, single-dose, placebo-controlled study are being presented ...

> Read More

Novasys - Renessa¬ģ Treatment for Female Incontinence Named Most Promising New Product Award Presented at Phoenix Conference of Medical Device CEOs

13 / 10 / 2009

NEWARK, CALIF., October 13, 2009 ‚?? Novasys Medical, Inc., a developer of innovative therapies in women‚??s health, announced today that its Renessa¬ģ non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers.

> Read More

Sunshine Heart - C-Pulse US Clinical Update Highlights Well Being of Four Initial Clinical Trial Patients

21 / 09 / 2009

Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today an update on the first four patients implanted with the C-Pulse device at The Ohio State University Medical Center in Columbus, Ohio and Jewish Hospital in Louisville, Kentucky.

> Read More

ChemGenex Submits New Drug Application for OMAPRO‚?Ę (Omacetaxine Mepesuccinate) to U.S. FDA

09 / 09 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO‚?Ę (omacetaxine mepesuccinate). OMAPRO‚?Ę is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

> Read More

ChemGenex to Present at Rodman & Renshaw Global Investment Conference in the U.S.

09 / 09 / 2009

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that Greg Collier, PhD, Chief Executive Officer and Managing Director will present a company update

> Read More

Peplin - LEO Pharma to Acquire Peplin for US$287.5m

03 / 09 / 2009

Peplin, Inc. (ASX:PLI) today announced a definitive merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash. This represents a purchase price of US$16.99 per common share of Peplin stock or A$1.03 per Peplin CHESS Depositary Interest (CDI).1

> Read More

GBS Portfolio Company Peplin Inc To Be Acquired by Leo Pharma for US$287.5m

03 / 09 / 2009

Peplin Inc (ASX:PLI), a clinical stage dermatology company, today announced a definitive agreement whereby Leo Pharma A/S (Leo), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will, subject to shareholder approval and other closing conditions, acquire all outstanding securities of Peplin.

> Read More

Novasys - Renessa¬ģ Treatment for Female Incontinence Gets Expanded Medicare Coverage

01 / 09 / 2009

Novasys Medical, Inc., a developer of innovative therapies in women‚??s health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC---- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia-----have agreed to cover the Renessa¬ģ treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.

> Read More

Verva Announces License of Key FGFR Intellectual Property to Isis Pharmaceuticals, Inc. for the Treatment of Obesity and Other Diseases

20 / 08 / 2009

Verva Pharmaceuticals Ltd. and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced the completion of an agreement providing Isis an exclusive license to Verva's intellectual property rights targeting the Fibroblast Growth Factor Receptor (FGFR) with antisense technology for the treatment of diseases, including obesity and other metabolic disorders. Isis also obtains a right of first refusal to license Verva's intellectual property rights targeting FGFR with mechanisms other than antisense, such as small molecule and antibody technologies. Verva received an undisclosed upfront payment and is eligible for future milestone payments and royalties.....

> Read More

Dr Julie Cherrington Joins Xenome Board

11 / 08 / 2009

Xenome Limited (‚??Xenome‚?Ě) today announced that Dr Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director....

> Read More

Sunshine Heart - First Female Patients in US Implanted with C-Pulse

10 / 08 / 2009

Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for advanced heart failure, announced today that Jewish Hospital in Louisville, Kentucky has completed implants of the Company‚??s C- PulseTM heart assist system in two female patients, ages fifty-eight and fifty-five, respectively, under a clinical trial approved by the US Food and Drug Administration (FDA). These procedures mark the first US female patients and the third and fourth patients treated with the C-Pulse heart assist system...

> Read More

 
Displaying records 1-25 of 59